## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL					
OMB Number: 3235-0287					
stimated average burden					
ours per response.	0.5				

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Typ	e Responses	)														
Name and Address of Reporting Person * Zarrabian Saiid				2. Issuer Name <b>and</b> Ticker or Trading Symbol DelMar Pharmaceuticals, Inc. [DMPI]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X Director 10% Owner				
(Last) (First) (Middle) C/O DELMAR PHARMACEUTICALS, INC., SUITE 720-999 WEST BROADWAY			3. Date of Earliest Transaction (Month/Day/Year) 05/21/2018							X Officer (give title below) Other (specify below)  President and CEO				)		
(Street) VANCOUVER, A1 V5Z 1K5			4. If Amendment, Date Original Filed(Month/Day/Year)						_X_	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person _Form filed by More than One Reporting Person						
(City) (State) (Zip)			Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned													
1.Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)			Date, if Code (Instr.		(	4. Securities Acqu (A) or Disposed of (Instr. 3, 4 and 5)		of (D) Owned Follow				Ownership Form: Direct (D)	Beneficial Ownership
							Code	v V	Amount	(A) or (D)	Price				or Indirect (I) (Instr. 4)	t (Instr. 4)
Security or E (Instr. 3) Pric Deri	Conversion	(Month/Day/Year)	3A. Deemed Execution Date, if	4. Transaction Code		5. Number of		ired, Disposed of, or Bene options, convertible securi of. Date Exercisable and Expiration Date (Month/Day/Year)				Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported	Ownersh Form of		
				Code	v	and 5)	(D)	Date Exercisal	Expira	ation	Title	Amount or Number of Shares	-	Transaction(s) (Instr. 4)	(s) (I) (Instr. 4)	
Employee Stock Option (right to buy)	\$ 0.9825	05/21/2018		A	v	836,465		(1)	05/21	1/2028	Commor Stock		\$ 0	836,465	D	
Report	ting O	wners														

Bonarding Comment Name / Addison	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Zarrabian Saiid C/O DELMAR PHARMACEUTICALS, INC. SUITE 720-999 WEST BROADWAY VANCOUVER, A1 V5Z 1K5	X		President and CEO			

## **Signatures**

/s/ Saiid Zarrabian	05/22/2018
Signature of Reporting Person	Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) 1/6th of the options vest on November 21, 2018 with the remaining shares vesting in equal monthly installments over a period of 30 months commencing on December 21, 2018.

 $Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, {\it see}\ Instruction\ 6 for procedure.$ 

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.